



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/gpss20>

One-Pot Stereoselective Synthesis of Alkyl (Z)-2-[4-Oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates from Acetylenic Esters and N, N' -Diphenylthiourea

Monireh Heshmati Gonbari ^a, Ali Ramazani ^a & Ali Souldozi ^a

^a Chemistry Department, Zanjan University, Zanjan, Iran

Version of record first published: 04 Feb 2009.

To cite this article: Monireh Heshmati Gonbari, Ali Ramazani & Ali Souldozi (2009): One-Pot Stereoselective Synthesis of Alkyl (Z)-2-[4-Oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates from Acetylenic Esters and N, N' -Diphenylthiourea, *Phosphorus, Sulfur, and Silicon and the Related Elements*, 184:2, 309-314

To link to this article: <http://dx.doi.org/10.1080/10426500802111488>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan,

sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

One-Pot Stereoselective Synthesis of Alkyl (Z)-2-[4-Oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates from Acetylenic Esters and N, N'-Diphenylthiourea

Monireh Heshmati Gonbari, Ali Ramazani,
and Ali Souldozi

Chemistry Department, Zanjan University, Zanjan, Iran

N, N'-diphenylthiourea reacts with dialkyl acetylenedicarboxylates in acetone to form 1:1 adducts, which undergo a cyclization reaction to produce alkyl (Z)-2-[4-oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates in fairly good yields. NMR spectra indicated that the reaction is completely stereoselective.

Keywords Acetylenic ester; Michael addition; N, N'-diphenylthiourea; stereoselectivity; 1,3-thiazolan


INTRODUCTION

For several years, acetylenic esters have been attracting the attention of organic chemists.^{1–13} Acetylenic esters are reactive systems and take part in many chemical syntheses.^{1–13} The compounds act almost as Michael acceptors in organic reactions.^{1–13} In recent years, there has been increased interest in the applications of acetylenic esters in multicomponent synthesis.^{1–13} Because of the atom economy, convergent character, and simplicity of one-pot procedures, multicomponent condensation reactions (MCRs) have an advantageous position among other reactions.^{1,14} The discovery and development of novel MCRs are receiving growing interest from industrial chemistry research groups, and MCRs represent a new challenge for organic chemists and to the basic understanding of organic chemistry itself.^{1,14} Owing to these characteristics and our interest in the synthesis of heterocycles,^{13–16} we were prompted to synthesize alkyl (Z)-2-[4-oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates (**5**) from N, N'-diphenylthiourea (**1**) and

Received 8 March 2008; accepted 8 April 2008.

This work was supported by the Zanjan University.

Address correspondence to Ali Ramazani, Chemistry Department Zanjan University, PO Box 45195-313, Zanjan, Iran. E-mail: aliramazani@gmail.com



SCHEME 1

dialkyl acetylenedicarboxylates (**2**) in acetone in fairly good yields (Scheme 1).

BIOLOGICAL AND INDUSTRIAL IMPORTANCE OF THIAZOLAN DERIVATIVES

Thiazolan^{17–19} skeletons are important compounds due to their broad range of biological activities.^{20–34} It is well known that thiazolyl derivatives possess anti-inflammatory properties.^{20–25} Today's requirements demand novel medicinal remedies possessing different degrees of selectivity and specificity depending on their purpose. The process of inflammation often becomes chronic, and the human organism needs drug therapy support in periods of acute attacks. Therefore, an increase of the variety of specific and selective anti-inflammatory remedies is an important task, especially due to its positive influence on the chronic sick rate decrease. Some anticancer drugs, such as bleomycine, and tiazofurin, that contain thiazolyl moiety in their structure, are known as antineoplastics.²⁶ In addition, several thiazolyl derivatives were found to be potent antitumor agents.^{26–28} Since arachidic acid (AA) metabolism results in the generation of mutagens that damage DNA and induce mutations, members of arachidic acid enzymes, especially the lipoxygenase pathway, have been reported to play a significant role in carcinogenesis. Inhibitors of AA metabolism can reverse the production of these metabolites resulting in recruitment

of apoptotic cell clearance.²⁹ Thiazole derivatives have attracted a great deal of interest owing to their antibacterial, antifungal, anti-inflammatory, and antiviral activities.³⁰ They are also useful as anti-allergic, anthelmintic agents and as sedative hypnotics.³⁰ It is also well known that the thiazole moiety can be important for significant biological activity.^{33,34} In addition to being used in the pharmaceutical industry,^{30–32} they also find wide applications in the dye and photographic industry.³⁰

RESULTS AND DISCUSSION

The compound (**5**) may result from an initial Michael addition reaction of N, N'-diphenylthiourea **1** to the acetylenic ester **2** and concomitant intramolecular protontransfer of the 1:1 adduct **3**, followed by attack of the imine nitrogen on the carbonyl group of ester to form product **5**, in acetone in fairly good yields (Scheme 1). TLC indicated that the reaction was completed after 15 min. The reaction proceeds smoothly and cleanly under the reaction conditions. The mechanism of the reaction has not been established experimentally. However, a possible explanation is proposed in Scheme 1. The formulas of the products **5a–b** were deduced from their IR, ¹H NMR, and ¹³C NMR spectra (See Experimental section). In this reaction, only one stereoisomer was observed, and therefore the reaction is completely stereoselective. Based on our previous reports in the areas of syntheses and structures (NMR data and single crystal X-ray structure determination)^{4,13,16} of electron-poor alkenes and comparison of the structural data with the structural data of the compounds **5** are *Z* (for example, for the *Z* stereoisomers, =CH of alkene showed distinct resonances at $\delta = 6.90\text{--}7.20$ ppm and for *E* stereoisomers, at $\delta = 5.80\text{--}6.60$ ppm in their ¹H NMR spectra).^{4,13,16} The IR spectrum of **5a** showed strong absorptions at 3062 (CH, aromatic), 2954 (CH, aliphatic), 1731 (C=O, ester), 1646 (C=N, imine), 1608 (C=C), and 1192 (C-O, ester) cm⁻¹ indicating the presence of mentioned groups in the formula. The ¹H NMR spectrum of **5a** compound exhibited four signals readily recognized as arising from one OMe groups ($\delta = 3.82$ ppm, s), CH ($\delta = 7.00$ ppm, s) and aromatic moieties ($\delta = 7.1\text{--}7.6$ ppm, m and $\delta = 6.95$ ppm, d, $^3J_{HH} = 8.0$ Hz). The ¹H decoupled ¹³C NMR spectrum of **5a** showed 14 distinct resonances in agreement with the **5a** formula. Partial assignment of these resonances is given in the spectral analysis section (see Experimental section). The ¹H and ¹³C NMR spectra of compound **5b** are similar to those of **5a**, except for the ester group,

which exhibits characteristic signals with appropriate chemical shifts (see Spectral Analysis section).^{3,4}

CONCLUSION

In summary, we have developed a new and efficient, one-pot stereoselective method for preparing of alkyl (*Z*)-2-[4-oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates (**5**) from *N*, *N'*-diphenylthiourea (**1**) and dialkyl acetylenedicarboxylates (**2**) in acetone in fairly good yields (Scheme 1). We believe the reported method offers a simple and efficient route for the preparation of the thiazoles **5** (Scheme 1). Its ease of work-up and fairly good yields make it a useful addition to modern synthetic methodologies.^{3,4} Other aspects of this process are under investigation.

EXPERIMENTAL

Melting points were measured on an Electrothermal 9100 apparatus and are uncorrected. IR spectra were recorded on a Mattson 1000 FT-IR spectrometer. ¹H and ¹³C NMR spectra were measured with a BRUKER Spectrospin spectrometer at 250 and 62.5 MHz, respectively.

General Procedure for the Preparation of Alkyl (*Z*)-2-[4-oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetates (**5a–b**)

To a magnetically stirred solution of *N*, *N'*-diphenylthiourea **1** (0.23 g, 1.0 mmol) in acetone (5 mL) was added dropwise a mixture of **2** (0.13 mL, 1.0 mmol) in acetone (2 mL) at -10°C over 15 min. The mixture was then stirred at -10°C for 15 min and then allowed to warm up to room temperature. The solvent was removed under reduced pressure, and products were recrystallized in ethanol (95%). The crystals of **5** were collected by simple filtration and dried at room temperature. The characterization data of the compounds (**5a–b**) are given below:

Selected Data for Methyl (*Z*)-2-[4-oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetate (**5a**)

Light yellow crystals, m. p. 117.5–118.5, yield 83%. IR (KBr) ($\nu_{\text{max}}, \text{cm}^{-1}$): 3062, 2954, 1731, 1646, 1608, 1500, 1377, 1323, 1192, 769, 700, and 585. ¹H NMR (CDCl₃) δ_{H} : 3.82 (3 H, s, OCH₃); 6.95 (2 H, d, ³*J*_{HH} = 8.0 Hz, arom.); 7.00 (1 H, s, =CH); 7.1–7.6 (8 H, m, arom.). ¹³C NMR (CDCl₃) δ_{C} : 52.57 (OCH₃), 116.49 (=CH); 120.90, 127.85, 129.30,

and 129.34 (8 CH, ortho and meta, arom.); 125.25 and 129.18 (2 CH, para, arom.); 133.98 and 147.32 (2 C, ipso, arom.); 141.42 (=CS); 151.57 (C=N); 164.56 and 166.36 (2 C=O).

Selected Data for Ethyl (Z)-2-[4-oxo-3-phenyl-2-(phenylimino)-1,3-thiazolan-5-yliden]acetate (5b)

Light yellow crystals, m. p. 87.5–88.5, yield 64%. IR (KBr) (ν_{\max} , cm^{-1}): 3060, 2923, 1723, 1646, 1377, 1315, 1200, 769, 700, and 585. ^1H NMR (CDCl_3) δ_{H} : 1.34 (3 H, t, $^3J_{\text{HH}} = 7.1$ Hz, CH_3); 4.28 (2 H, q, $^3J_{\text{HH}} = 7.1$ Hz, OCH_2); 6.96 (2 H, d, $^3J_{\text{HH}} = 7.5$ Hz, arom.); 6.99 (1 H, s, =CH); 7.1–7.6 (8 H, m, arom.). ^{13}C NMR (CDCl_3) δ_{C} : 14.14 (CH_3); 61.78 (OCH_2); 116.95 (=CH); 120.90, 127.85, 129.28, and 129.35 (8 CH, ortho and meta, arom.); 125.21 and 129.17 (2 CH, para, arom.); 133.97 and 147.34 (2 C, ipso, arom.); 141.13 (=CS); 151.77 (C=N); 164.63 and 165.98 (2 C=O).

REFERENCES

- [1] A. Ramazani, A. R. Kazemizadeh, E. Ahmadi, N. Noshiranzadeh, and A. Souldozi, *Curr. Org. Chem.*, **12**, 59 (2008).
- [2] A. Ramazani, A. Abbasi Motejadded, and E. Ahmadi, *Phosphorus, Sulfur, and Silicon*, **181**, 233 (2006) and references cited therein.
- [3] A. Ramazani and S. A. Hossaini-Alemi, *Phosphorus, Sulfur, and Silicon*, **176**, 237 (2001).
- [4] A. Ramazani, A. Morsali, A. A. Soudi, A. Souldozi, Z. A. Strarikova, and A. Yanovsky, *Z. Kristallogr., NCS*, **218**, 33 (2003).
- [5] I. Yavari and A. Ramazani, *Synth. Commun.*, **27**, 1449 (1997).
- [6] A. Ramazani and A. Bodaghi, *Tetrahedron Lett.*, **41**, 567 (2000).
- [7] I. Yavari, A. Ramazani, and A. Yahya-Zadeh, *Synth. Commun.*, **26**, 4495 (1996).
- [8] A. Ramazani, B. Mohammadi, and N. Noshiranzadeh, *Phosphorus, Sulphur, and Silicon*, **178**, 545 (2003).
- [9] A. Ramazani, B. Mohammadi, and N. Noshiranzadeh, *Phosphorus, Sulfur, and Silicon*, **178**, 767 (2003).
- [10] A. Ramazani, N. Noshiranzadeh, and B. Mohammadi, *Phosphorus, Sulfur, and Silicon*, **178**, 761 (2003).
- [11] A. Ramazani, N. Noshiranzadeh, and B. Mohammadi, *Phosphorus, Sulfur, and Silicon*, **178**, 539 (2003).
- [12] A. Ramazani and H. Ahani, *Phosphorus, Sulfur, and Silicon*, **170**, 181 (2001).
- [13] A. Souldozi, A. Ramazani, N. Bouslimani, and R. Welter, *Tetrahedron Lett.*, **48**, 2617 (2007).
- [14] N. Noshiranzadeh and A. Ramazani, *Synth. Commun.*, **37**, 3181 (2007) and references cited therein.
- [15] A. Souldozi and A. Ramazani, *Tetrahedron Lett.*, **48**, 1549 (2007).
- [16] A. Ramazani, A. Morsali, B. Ganjeie, A. R. Kazemizadeh, E. Ahmadi, R. Kempe, and I. Hertle, *Z. Naturforsch.*, **60b**, 569 (2005).
- [17] I. Yavari, S. Ali-Asgari, K. Porshamsian, and M. Bagheri, *Journal of Sulfur Chemistry*, **28**, 477 (2007).

- [18] I. Yavari, N. Hosseini, and L. Moradi, *Monatshefte für Chemie / Chemical Monthly*, **139**, 133 (2008).
- [19] I. Yavari, M. Sabbaghan, K. Porshamsian, M. Bagheri, S. Ali-Asgari, and Z. Hos-saini, *Molecular Diversity*, **11**, 81 (2007).
- [20] M. B. Roberfroid, H. G. Viehe, and J. Remacle, Inflammatory and antiinflammatory process, in *Advances in Drug Research*, B. Testa, Ed., vol. **16**, p. 50, (Academic Press, London, UK, 1987).
- [21] T. J. Shen, Nonsteroidal anti-inflammatory agents, part III, in *Burger's Medicinal Chemistry*, M. E. Wolf, Ed., pp. 1205–1272, (John Wiley & Sons, New York, NY, USA, 4th edition, 1981).
- [22] A. A. Geronikaki and D. Hadjipavlou-Litina, *Pharmazie*, **48**, 948 (1993).
- [23] R. Mgonzo, A. Geronikaki, and P. N. Kourounakis, *Pharmazie*, **50**, 505 (1995).
- [24] D. Hadjipavlou-Litina, A. Geronikaki, R. Mgonzo, and I. Doytchinova, *Drug Devel-opment Research*, 53 (1999).
- [25] A. Geronikaki, D. Hadjipavlou-Litina, C. Chatziopoulos, and G. Soloupis, *Molecules*, **8**, 472 (2003).
- [26] G. W. A. Milne, Ed., *Ashgate Handbook of Antineoplastic Agents*, Gower, London, UK, 2000.
- [27] X.-H. Gu, X.-Z. Wan, and B. Jiang, *Bioorganic and Medicinal Chemistry Letters*, **9**, 569 (1999).
- [28] B. Jiang and X.-H. Gu, *Bioorganic and Medicinal Chemistry*, **8**, 363 (2000).
- [29] E. Pontiki and D. Hadjipavlou-Litina, *Current Enzyme Inhibition*, **1**, 309 (2005).
- [30] M. V. Ramana, D. S. Dubhashi, and J. J. D'Souza, *J. Chem. Research (S)*, 496 (1998) and references cited therein.
- [31] S. D. Larsen, C. F. Stachew, P. M. Clare, J. W. Cubbage, and K. L. Leach, *Bioorg. Med. Chem. Lett.*, **13**, 3491 (2003) and references cited therein.
- [32] A. Gebert¹, A. Linden, G. Mloston, and H. Heimgartner, *Polish J. Chem.*, **77**, 867 (2003) and references cited therein.
- [33] R. Mgonzo, A. Geronikaki, and G. Theophilidis, *Research Communications in Phar-macology and Toxicology*, **1**, 137 (1996).
- [34] A. Geronikaki and G. Theophilidis, *European Journal of Medicinal Chemistry*, **27**, 709 (1992).